Please ensure Javascript is enabled for purposes of website accessibility

Why AnaptysBio, Co-Diagnostics, and Novavax Are Getting Crushed Today

By George Budwell - Mar 9, 2020 at 4:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A pair of black swans crushed these three healthcare stocks today.

What happened

The three healthcare stocks AnaptysBio, Inc. (ANAB 4.92%), Co-Diagnostics, Inc. (CODX -30.65%), and Novavax, Inc. (NVAX 2.80%) are all taking it on the chin this dark and gloomy Monday. AnaptysBio's stock fell by as much as 13.4%, Co-Diagnostics' shares dipped by as much as 26%, and Novavax's equity shed 23.1% of its value at one point today. These healthcare names have each clawed back from their lows, but they all remain down by at least 10% as of 2 p.m. EDT. 

What's weighing on this trio of healthcare stocks today? A pair of black swans. First, crude oil prices collapsed over the weekend due OPEC's inability to reach a deal with Russia. Second, COVID-19 appears poised to trigger a worldwide economic recession due to its negative impact on the global supply chain.  

A pair of black swans swimming in a pond.

Image source: Getty Images.

So what

Prior to today's drama, shares of AnaptysBio, Co-Diagnostics, and Novavax were all in positive territory for the year. AnaptysBio's stock was on the mend after a tough 2019, thanks to the growing optimism about several upcoming clinical and regulatory milestones slated for later this year. The biotech's collaboration with GlaxoSmithKline for their endometrial cancer drug, dostarlimab, also seemed to be attracting investors to its shareholder ranks this year. 

The molecular diagnostic company Co-Diagnostics was in the midst of a stunning breakout before today due to its easy-to-use COVID-19 test kit. The company's shares, in fact, were up by over 1,300% for the year only a few days ago. 

Novavax, for its part, was also up by over 200% for the year prior to today's downward slide. Investors were piling onto this clinical-stage biotech in anticipation of the company's forthcoming phase 3 NanoFlu results, as well as its experimental vaccine against COVID-19.

Now what

All of this positive momentum came to an abrupt halt today because of plunging crude oil prices and concerns about the economic impact of this deadly respiratory disease. That's the good news, in a sense. More specifically, these three healthcare stocks aren't tanking because of company-specific setbacks. So, if you liked these names last week, there's no logical reason not to add to your position on this pullback. After all, AnaptysBio, Co-Diagnostics, and Novavax all still sport the same fundamental value proposition they did at the end of the last week.  

 

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends GlaxoSmithKline. The Motley Fool recommends AnaptysBio. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$41.47 (2.80%) $1.13
AnaptysBio Stock Quote
AnaptysBio
ANAB
$26.23 (4.92%) $1.23
Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
CODX
$4.48 (-30.65%) $-1.98
GSK Stock Quote
GSK
GSK
$1,450.00 (3.57%) $50.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.